Accès ouvert
2026
article
OpenAlex
Bianca Arianna Facchini, Agostina Lagodin D'amato, Ester Simeone, Margaret Ottaviano et autres
Background Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for several solid tumors. Among the mechanisms investigated to explain variability in ICIs efficacy, the potential effect of the time-of-day (ToD) at which ICIs are administered has emerged as an area of …
it
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Eleonora Cioli, Gabriella Suarato, Rossella Napolitano, Francesco Caraglia et autres
Background: Recent advancements in cancer treatment have shifted the paradigm from chemotherapy to targeted therapies and immunotherapies, proving effective even in early-stage cancers. Regulatory agencies like the Food and Drug Administration, European Medicines Agency, and Italian Agency for Drugs have approved several …
it, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Domenico Mallardo, Francesca Sparano, Maria Grazia Vitale, Claudia Trojaniello et autres
Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was performed to evaluate the survival of patients with cutaneous squamous cell carcinoma (CSCC) who …
it
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Domenico Mallardo, Francesca Sparano, Maria Grazia Vitale, Claudia Trojaniello et autres
Abstract Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was performed to evaluate the survival of patients with cutaneous squamous cell carcinoma (CSCC) …
it, ch, de, jp
(code pays fourni par la source)
Accès ouvert
2023
conference-paper
OpenAlex
Domenico Mallardo, Francesca Sparano, Maria Grazia Vitale, Claudia Trojaniello et autres
Background Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer in white-skinned populations. Advanced or metastatic disease is rare, less than 5% of patients (pts), but when it occurs, is difficult to treat and often has a poor prognosis. …
it
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Domenico Mallardo, Francesca Sparano, Maria Grazia Vitale, Claudia Trojaniello et autres
As evidence for the role of ICI discontinuation before progression of cutaneous squamous cell carcinoma (CSCC) is lacking, a retrospective study was performed to evaluate the survival of patients who discontinued cemiplimab without progression due to different causes.
it
(code pays fourni par la source)
Accès ouvert
2023
review
OpenAlex
Vito Amoroso, F. Gallo, Andrea Alberti, D. Paloschi et autres
Background: Immune-related adverse events (irAEs) are frequently reported during immune checkpoint inhibitor (ICI) therapy and are associated with long-term outcomes.It is unknown if the irAE occurrence is a valid surrogate of ICIs' efficacy.Methods: We identified articles reporting the results of randomized trials …
ca, it
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Domenico Mallardo, Diana Giannarelli, Maria Grazia Vitale, Domenico Galati et autres
BACKGROUND: Nivolumab is an anti-PD-1 antibody approved for treating metastatic melanoma (MM), for which still limited evidence is available on the correlation between drug exposure and patient outcomes. METHODS: In this observational retrospective study, we assessed whether nivolumab concentration is associated with …
it, us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Domenico Mallardo, Diana Giannarelli, Domenico Galati, Maria Grazia Vitale et autres
Nivolumab is an anti-PD1 antibody approved for the treatment of metastatic melanoma (MM), for which still limited evidence is available on the correlation between drug exposure and patient’s outcomes. In this observational retrospective study we assessed whether nivolumab concentration is associated with …
it, us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Domenico Mallardo, Diana Giannarelli, Domenico Galati, Maria Grazia Vitale et autres
Nivolumab is an anti-PD1 antibody approved for the treatment of metastatic melanoma (MM), for which still limited evidence is available on the correlation between drug exposure and patient’s outcomes. In this observational retrospective study we assessed whether nivolumab concentration is associated with …
it, us
(code pays fourni par la source)
Accès ouvert
2021
conference-paper
OpenAlex
Domenico Mallardo, Maria Grazia Vitale, Diana Giannarelli, Giusy Trillò et autres
Background Nivolumab (nivo) is a monoclonal antibody that targets programmed death-1 (PD-1) molecule and has been approved for the treatment of several solid tumors; in the treatment of adjuvant and metastatic melanoma had better efficacy compared with chemotherapy or ipilimumab (anti-CTLA4).1–4 The …
it, us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli et autres
BACKGROUND: Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in patients with BRAFV600E melanoma …
it, us
(code pays fourni par la source)